Gilead's second HIV pre exposure prophylaxis (PrEP) medication has been approved for marketing
JESUS60
发表于 2024-1-8 20:29:13
1271
0
0
On January 8th, according to the official WeChat account of Geely Technology, DaKeWei& Reg; Enqutabine Propenofovir Tablets (II), Enqutabine 200mg/Propenofovir 25mg, F/TAF) have been approved by the National Medical Products Administration (NMPA) for pre exposure prophylaxis (PrEP) for adults and adolescents at least 35kg in weight at risk of human immunodeficiency virus type 1 (HIV-1) infection, to reduce the risk of HIV-1 infection due to high-risk sexual behavior. Previously, Gilead Entratabine Propenofovir Tablets had been approved in China for use in combination with other antiretroviral drugs in the treatment of HIV-1 infections in adults and adolescents (aged 12 years and above and weighing at least 35kg).
Pre exposure prevention refers to the use of specific antiviral drugs by individuals who have not yet been infected with HIV before engaging in behaviors that are susceptible to HIV infection, in order to prevent HIV infection. It is an important biomedical measure for HIV prevention. In August 2020, Gilead Scientific Enqutabine Tenofovir tablets were approved, becoming the first drug in China approved for pre exposure prevention of HIV in uninfected populations.
At present, sexual transmission has become the main route of HIV transmission in China. More than 95% of newly diagnosed HIV infected individuals in our country are infected through sexual means, and unsafe sexual behavior is the main cause of HIV sexual transmission. Unsafe sexual behaviors with a high risk of HIV infection include unprotected male same-sex sex, non fixed sexual partners, and paid sex.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Eli Lilly AD new drug approved for market launch, lencamab meets strong competitors
- Eli Lilly and Predator Peptide Approved for Long term Weight Management Indications in China
- Tesla Musk: Expected FSD to be approved and implemented in China before the end of the year
- The Class 1 new drug introduced by Anjin with over 1 billion US dollars has been approved for clinical use
- JD Allianz Equity Transfer Approved: Allianz Insurance Group to Transfer 53.33% Equity of the Company to Allianz China Holdings
- Sanofi: Targeted therapy drug for chronic obstructive pulmonary disease (COPD), Dabitou, approved in China
- Intel Technology is expected to complete $8.5 billion in financing by the end of the year; A total of 109 domestic online games were approved in September
- Johnson&Johnson's drug Zebaike has been approved in China
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
-
苹果知名分析师郭明錤周四(10月31日)在社交媒体上发文表示,苹果明年可能会减少对芯片制造商博通Wi-Fi芯片的依赖,并推出自己的处理器。 郭明錤在社交媒体平台X上写道,“在2025年下半年的新产品(例如iPh ...
- uturn
- 前天 14:42
- 支持
- 反对
- 回复
- 收藏
-
10月30日,小鹏汽车生态企业小鹏汇天宣布,旗下分体式飞行汽车“陆地航母”即将亮相2024中国航展,11月12日将在中国航展第二展区(斗门莲洲)进行全球首次公开飞行,同时“陆地航母”也将在珠海国际航展中心8号 ...
- yxtianyouyou
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
交易所监管文件显示,当地时间11月1日,亚马逊创始人杰夫·贝索斯拟出售约1635万股亚马逊股票,预计套现约30.5亿美元。今年7月,贝索斯已申请额外出售约2500万股亚马逊股票,按当时股价计算可套现约50亿美元。 ...
- blueskybb
- 昨天 09:27
- 支持
- 反对
- 回复
- 收藏
-
近日,凯撒海湾目的地(山东)运营管理有限责任公司(简称“凯撒海湾”)与携程旅悦集团签署战略合作协议,双方将围绕“海上目的地运营”、“旅游产品与服务创新”、“研学旅行”、“日韩及海外旅游市场开拓”等 ...
- llyyy2008
- 昨天 11:01
- 支持
- 反对
- 回复
- 收藏